Olr1060 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the Olr1060 protein, which is an olfactory receptor within the G-protein-coupled receptor (GPCR) superfamily. These receptors are crucial components of the olfactory system, responsible for detecting odorant molecules and initiating the signal transduction pathways that lead to the perception of smell. Olr1060 is expressed in the membranes of olfactory sensory neurons located in the nasal epithelium. When an odorant binds to Olr1060, the receptor undergoes a conformational change that activates an intracellular signaling cascade involving G-proteins. This cascade ultimately leads to the generation of an electrical signal that is transmitted to the brain, where it is interpreted as a specific odor. Inhibitors of Olr1060 are small molecules that are designed to bind to the receptor's odorant-binding site or other critical functional regions, thereby blocking the receptor's ability to interact with its natural ligands. This inhibition prevents the receptor from initiating the olfactory signal transduction process, effectively modulating the perception of odors associated with Olr1060.
The development of Olr1060 inhibitors involves a comprehensive understanding of the receptor's structural biology and the molecular interactions that are essential for its function. Researchers typically employ high-throughput screening techniques to identify initial lead compounds that demonstrate the ability to inhibit Olr1060. These lead compounds are then refined through structure-activity relationship (SAR) studies, where their chemical structures are systematically modified to enhance binding affinity, specificity, and stability within the receptor's binding pocket. The chemical structures of Olr1060 inhibitors are diverse, often incorporating functional groups that facilitate strong and specific interactions with the receptor, such as hydrogen bonding, hydrophobic interactions, and van der Waals forces. Advanced structural biology techniques, including X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are employed to visualize these interactions at an atomic level, providing valuable insights that guide the design and refinement of these inhibitors. Achieving high selectivity is a critical objective in the development of Olr1060 inhibitors, ensuring that these compounds specifically target Olr1060 without affecting other olfactory receptors or GPCRs that share similar structural features. This selectivity is essential for enabling precise modulation of Olr1060 activity, allowing researchers to explore its specific role in olfactory perception and to deepen their understanding of the molecular mechanisms underlying the sense of smell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
Targets EGFR tyrosine kinase, potentially altering pathways intersecting with Olr1060's signaling. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Dual inhibitor of EGFR and HER2 tyrosine kinases, could impact Olr1060 activity via related pathways. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Selective BCR-ABL inhibitor, potentially modulates signaling pathways intersecting with Olr1060. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
CDK4/6 inhibitor, might indirectly influence Olr1060 through cell cycle regulation pathways. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Inhibits VEGFR, PDGFR, and c-Kit, potentially affecting Olr1060 through angiogenesis and growth factor signaling. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Multi-kinase inhibitor, could modulate various signaling pathways including those related to Olr1060. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
CDK4/6 inhibitor, potentially impacts signaling cascades that intersect with Olr1060's functions. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK inhibitor, could influence Olr1060 activity by modulating the MAPK/ERK pathway. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Inhibits VEGFR, EGFR, and RET tyrosine kinases, might affect Olr1060 signaling through angiogenesis and growth factor pathways. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
BCL-2 inhibitor, potentially influences apoptotic pathways intersecting with Olr1060's activity. |